[CRIS] Curis, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 3.37 Change: 0.15 (4.66%)
Ext. hours: Change: 0 (0%)

chart CRIS

Refresh chart

Strongest Trends Summary For CRIS

CRIS is in the medium-term up 91% in 6 months. In the long-term down -91% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Curis, Inc. is engaged in the research, development, and commercialization of cancer therapeutics. It focuses on developing cancer drug candidates, including CUDC-907, an oral, small molecule drug candidate that is designed to inhibit histone deacetylase and phosphatidylinositol-3-kinase, or PI3K enzymes; CUDC-427, an oral, small molecule drug candidate, which is designed to promote cancer cell death by antagonizing inhibitor of apoptosis proteins; Erivedge, an orally-administered small molecule Hedgehog pathway inhibitor; and Debio 0932, a small molecule inhibitor of heat shock protein 90. It has collaborations with Genentech, Inc. and F. Hoffmann-La Roche Ltd. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -65.47% Sales Growth - Q/Q-16.81% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-37.73% ROE-51.38% ROI-41.08%
Current Ratio10.54 Quick Ratio Long Term Debt/Equity0.23 Debt Ratio0.11
Gross Margin96.5% Operating Margin-412.36% Net Profit Margin-440.57% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities64.06 M Cash From Investing Activities-40.58 M Cash From Operating Activities-7.76 M Gross Profit1.57 M
Net Profit-31.85 M Operating Profit-31.02 M Total Assets119.31 M Total Current Assets102.55 M
Total Current Liabilities9.73 M Total Debt27.38 M Total Liabilities31.69 M Total Revenue1.66 M
Technical Data
High 52 week3.03 Low 52 week0.62 Last close1.64 Last change-9.89%
RSI37.84 Average true range0.13 Beta1.08 Volume507.06 K
Simple moving average 20 days-10.59% Simple moving average 50 days-9.25% Simple moving average 200 days12.65%
Performance Data
Performance Week-10.38% Performance Month-9.89% Performance Quart57.69% Performance Half11.56%
Performance Year-41.81% Performance Year-to-date137.75% Volatility daily3.44% Volatility weekly7.69%
Volatility monthly15.76% Volatility yearly54.61% Relative Volume533.41% Average Volume599.09 K
New High New Low

News

2019-06-12 07:00:00 | Curis Highlights Publication in Nature Cell Biology Identifying Cancer-Causing Form of IRAK4 in Patients with AML and MDS

2019-05-14 21:03:39 | Edited Transcript of CRIS earnings conference call or presentation 14-May-19 8:30pm GMT

2019-05-14 16:29:33 | Curis: 1Q Earnings Snapshot

2019-05-14 16:05:00 | Curis Reports First Quarter 2019 Financial Results

2019-05-07 08:00:00 | Curis to Release First Quarter Financial Results and Hold Conference Call on May 14, 2019

2019-05-06 08:00:00 | Curis Completes Mesothelioma Enrollment in CA-170 Study

2019-04-26 15:13:48 | Some Curis NASDAQ:CRIS Shareholders Have Taken A Painful 83% Share Price Drop

2019-04-10 08:00:00 | Curis Regains Compliance with Nasdaq Continued Listing Requirements

2019-04-05 16:30:00 | Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2019-03-27 22:16:54 | Edited Transcript of CRIS earnings conference call or presentation 26-Mar-19 8:30pm GMT

2019-03-26 16:17:25 | Curis: 4Q Earnings Snapshot

2019-03-26 16:00:00 | Curis Reports Fourth Quarter and Year-End 2018 Financial Results

2019-03-26 07:36:32 | The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs

2019-03-25 12:05:51 | What's Driving The Rally In Microcap Biotech Curis?

2019-03-25 11:46:02 | Biotech News: Why Curis Stock Is Soaring Today

2019-03-25 09:26:00 | Curis' stock rockets on heavy volume after $135.7 million deal to sell portion of Erivedge royalties

2019-03-25 08:30:00 | Curis Sells Portion of Erivedge Royalties to Oberland Capital for up to $135.7 million

2019-03-25 07:30:00 | Curis to Release Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on March 26, 2019

2019-03-04 08:00:00 | Curis Announces Presentation at Cowen & Company 39th Annual Healthcare Conference

2019-02-04 07:00:00 | Curis, Inc. to Present at the 2019 BIO CEO & Investor Conference

2019-01-29 09:30:02 | Has Curis CRIS Outpaced Other Medical Stocks This Year?

2019-01-24 07:00:00 | First Mesothelioma Patient Dosed in CA-170 Study

2019-01-10 17:53:38 | First Eagle Slashes Curis Stake at Substantial Loss

2019-01-10 09:30:02 | Is Curis CRIS Outperforming Other Medical Stocks This Year?

2019-01-08 12:58:13 | Top 3 Healthcare Penny Stocks for 2018

2019-01-04 16:00:00 | Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2018-11-30 07:45:00 | Analysis: Positioning to Benefit within Dicerna Pharmaceuticals, Sun Life Financial, Autodesk, Eagle Pharmaceuticals, Curis, and Accenture — Research Highlights Growth, Revenue, and Consolidated Results

2018-11-20 10:45:00 | Curis to Present at the 60th Annual Meeting of the American Society of Hematology

2018-11-07 16:05:00 | Curis to Present at 33rd Society for Immunotherapy of Cancer Annual Meeting and Cowen IO NEXT Summit

2018-11-02 10:00:33 | Edited Transcript of CRIS earnings conference call or presentation 1-Nov-18 12:30pm GMT

2018-11-01 10:41:02 | Curis CRIS Reports Q3 Loss, Tops Revenue Estimates

2018-11-01 09:04:11 | Curis: 3Q Earnings Snapshot

2018-11-01 07:00:00 | Curis Reports Third Quarter 2018 Financial Results

2018-10-23 16:29:00 | Curis to Release Third Quarter Financial Results and Hold Conference Call on November 1, 2018

2018-10-23 08:45:00 | Investor Expectations to Drive Momentum within Ormat Technologies, The Andersons, Freshpet, Curis, Ultra Clean, and Edge Therapeutics — Discovering Underlying Factors of Influence

2018-10-19 10:39:02 | Curis CRIS Shares March Higher, Can It Continue?

2018-10-10 18:44:00 | Top 3 Healthcare Penny Stocks for 2018

2018-10-05 07:00:00 | Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2018-09-27 11:44:36 | Who Are The Top Investors In Curis Inc NASDAQ:CRIS?

2018-09-26 16:05:00 | Curis to Present at the Cantor Fitzgerald Global Healthcare Conference

2018-09-24 16:22:00 | Curis Announces Leadership Change

2018-08-29 07:45:00 | Report: Developing Opportunities within Q2, Ormat Technologies, The Andersons, Comstock Resources, Freshpet, and Curis — Future Expectations, Projections Moving into 2018

2018-08-28 16:14:00 | Curis to Present at the Baird 2018 Global Healthcare Conference

2018-08-02 11:50:03 | Curis CRIS Reports Q2 Loss, Lags Revenue Estimates

2018-08-02 11:11:48 | Edited Transcript of CRIS earnings conference call or presentation 2-Aug-18 12:30pm GMT

2018-08-02 10:45:41 | Curis: 2Q Earnings Snapshot

2018-08-02 07:00:00 | Curis Reports Second Quarter 2018 Financial Results

2018-07-27 08:30:00 | Curis to Release Second Quarter Financial Results and Hold Conference Call on August 2, 2018

2018-07-26 07:55:00 | Consolidated Research: 2018 Summary Expectations for At Home Group, Royal Bank Of Canada, Curis, Novavax, HNI, and Freshpet — Fundamental Analysis, Key Performance Indications

2018-07-23 09:18:00 | Top 3 Healthcare Penny Stocks for 2018